Associate chief physician | Sir Run Run Shaw Hospital, Zhejiang University School of Medicine | China
Dr. Sheng Jin is an Associate Chief Physician at the Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine. With a strong background in molecular gene analysis and precision treatment, she specializes in lung cancer and digestive tract tumors. Dr. Sheng has been at the forefront of clinical oncology research, contributing to over 40 published studies in esteemed journals. Her work focuses on innovative therapies, including molecular targeted treatments, chemotherapy, and immunotherapy, helping shape the future of personalized cancer treatment.
Profile👤
ORCID
Strengths for the Awards✨
✅ Extensive Research Contributions – Dr. Sheng Jin has published over 40 research articles in highly regarded oncology journals, such as NPJ Precision Oncology, The Oncologist, and Lung Cancer, demonstrating her strong research presence.
✅ Clinical Research Impact – She has participated in over 50 international and domestic multi-center clinical studies on anti-tumor drugs, reflecting her significant role in advancing precision oncology.
✅ Expertise in Oncology & Precision Medicine – Her research in molecular gene analysis and precision treatment of lung cancer and digestive tract tumors showcases her as a leader in targeted therapies.
✅ Leadership in Oncology Societies – Dr. Sheng is actively involved in various professional committees, including the Chinese Society of Clinical Oncology (CSCO), which highlights her influence in the field.
✅ Innovative Contributions – Her recent work on MET-TKI therapy in NSCLC has provided valuable insights into potential treatments for lung cancer patients, reinforcing her pioneering role in personalized medicine.
Education 🎓
Dr. Sheng Jin earned her M.D. in Oncology and Clinical Medicine from Sun Yat-sen University in 2016. Following her medical degree, she pursued postdoctoral training at Zhejiang University School of Medicine, completing it in 2019. This rigorous academic journey provided her with expertise in oncological research and precision medicine, laying the foundation for her impactful career in clinical oncology.
Experience 💼
Dr. Sheng Jin has amassed extensive clinical and research experience. As an Associate Chief Physician, she has led and participated in over 50 international and domestic multi-center clinical studies focusing on anti-tumor drugs. Her research delves into advanced treatment strategies for various malignancies, ensuring better patient outcomes. She also plays an integral role in national oncology research projects and professional committees, contributing to advancements in cancer therapy and patient care.
Research Interests On Oncology 🔬
Dr. Sheng’s research interests revolve around:
- Molecular targeted therapy and immunotherapy for lung, gastric, colon, and pancreatic cancers.
- Precision medicine and molecular gene analysis in oncology.
- Development of innovative chemotherapy regimens.
- Comprehensive management of solid tumors, including palliative care and case management. Her expertise in these areas has positioned her as a leading figure in advancing precision oncology and improving therapeutic strategies.
Awards 🏆
Dr. Sheng Jin has received multiple accolades for her contributions to oncology research and clinical practice. Her pioneering studies in precision medicine and targeted therapies have earned her recognition at both national and international levels. She has also been actively involved in shaping clinical guidelines for managing cancer-related symptoms, further cementing her status as a distinguished researcher and physician.
Publications 📚
Dr. Sheng Jin has authored numerous influential publications in peer-reviewed journals. Below are some of her notable works:
-
Non-small cell lung cancer with SMARCA4 deficiency harboring rare EGFR mutations exhibited significant tumor response when treated with afatinib: a case report
- Authors: Xiaotong Qiu, Liangkun You, Chongwei Wang, Jin Sheng
- Publication Year: 2025
-
BPI-28592 as a novel second-generation inhibitor for NTRK fusion tumors
- Authors: Jin Sheng, Hong Chen, Bang Fu, Hongming Pan, Jiabing Wang, Weidong Han
- Publication Year: 2024
-
Tislelizumab combined with GT chemotherapy for intimal sarcoma of inferior vena cava: A case report
- Authors: Haihong Liao, Yong Fang, Da Li, Yuefen Pan, Zhongfeng Niu, Tianhong Fu, Zhuoxuan Wu, Jin Sheng, Yong Dong, Shuwen Han, Quan Qi, Yulong Liu
- Publication Year: 2024
-
Rare SMARCA4-deficient thoracic tumor: Insights into molecular characterization and optimal therapeutics methods
- Authors: M. Shi, Lanlan Pang, Huaqiang Zhou, Shi-Jing Mo, Jin Sheng, L. Zhang, Jiaqing Liu, Dongchen Sun, Long-Long Gong, Jiawei Wang, Wu Zhuang, Yihua Huang, Zefeng Chen, Yuanyuan Zhao, Wen-Feng Fang
- Publication Year: 2024
-
Impact of prophylactic dexamethasone on the efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy in patients with advanced non-squamous non-small-cell lung cancer
- Authors: Hui Yu, Jianqi Chen, Yixin Zhou, Jin Sheng, Xuanye Zhang, Li-Na He, Likun Chen, Q. Chu, Li Zhang, Shaodong Hong
- Publication Year: 2023
-
Integrated Analysis Identifies DPP7 as a Prognostic Biomarker in Colorectal Cancer
- Authors: Wei Zhang, Haidong Wang, Huadi Wang, Chuchu Xu, Rongjie Zhao, Junlin Yao, Weidong Han, Weidong Han, Hongming Pan, Jin Sheng
- Publication Year: 2023
-
Impact of Prophylactic Dexamethasone on the Efficacy of Immune Checkpoint Inhibitors Plus Platinum-based Chemotherapy in Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer
- Authors: YU HUI, Jiaojiao Chen, Jin Sheng, Yuchi Zhou, Xuanye Zhang, Li-Na He, Q. Chu, Lin-Zhou Zhang, Shaodong Hong
- Publication Year: 2023
-
Immunochemotherapy achieved a complete response for metastatic adenocarcinoma of unknown primary based on gene expression profiling: a case report and review of the literature
- Authors: Jin Sheng, Hongming Pan, Weidong Han
- Publication Year: 2023
-
Thoracic SMARCA4-Deficient Undifferentiated Tumor With ALK Fusion Treated With Alectinib Achieved Remarkable Tumor Regression: Case Report
- Authors: Jin Sheng, Weidong Han, Hongming Pan
- Publication Year: 2023
-
CD3+CD4-CD8- (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer
- Authors: Zhiheng Wu, Yi Zheng, Jin Sheng, Yicheng Han, Yanyan Yang, Hongming Pan, Junlin Yao
- Publication Year: 2022
Conclusion 🏅
Dr. Sheng Jin’s dedication to precision oncology has significantly advanced cancer treatment methodologies. Her research contributions, clinical expertise, and commitment to improving patient outcomes have solidified her position as a leader in medical oncology. By bridging the gap between molecular research and clinical application, she continues to pave the way for innovative and personalized cancer therapies. Her ongoing efforts in targeted therapies and immunotherapy promise to make a lasting impact in the fight against cancer.
